Accession Therapeutics Initiates First Patient Dosing in Clinical Trial
Accession Therapeutics Limited is making significant strides in the field of cancer treatment by announcing the dosing of the first patient in its Phase 1 clinical trial for TROCEPT-01 (ATTR-01). This groundbreaking development is centered on a next-generation immunotherapy approach that aims to enhance cancer treatment efficacy.
TROCEPT-01: A Revolutionary Cancer Treatment
TROCEPT-01 (ATTR-01) is being hailed as a first-in-class, tumour-activated viral immunotherapy. The therapy’s design allows it to selectively generate a clinically validated checkpoint inhibitor specifically within tumours. This innovative mechanism focuses on ?v?6 integrin present on epithelial tumours, optimizing the therapeutic effect while protecting healthy tissues from damage.
Significant Preclinical Results
Before its clinical application, TROCEPT-01 has demonstrated compelling anti-tumour activity in various preclinical studies involving multiple solid tumour models. The preclinical data suggests that it could offer new hope as a targeted therapy for aggressive forms of cancer, enhancing clinical outcomes where current treatments fall short.
Understanding the ATTEST Trial
The ATTEST trial is an open-label, dose-escalation, and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TROCEPT-01 (ATTR-01) in advanced carcinoma patients who have previously undergone treatment. This trial represents a significant collaborative effort being conducted across prominent clinical sites in the UK, with further expansions planned in locations with established expertise in the management of solid tumours.
Insights from Key Contributors
Professor Adel Samson, a renowned Cancer Medicine and Immunotherapy professor at Leeds University, expressed his enthusiasm for TROCEPT-01, highlighting its potential to enhance clinical response rates through strategic tumour-localised drug production.
CEO Bent Jakobsen acknowledged the first patient dosing as a pivotal moment for Accession Therapeutics and recognized the commitment of the team and collaborators in breaking new ground with this unique platform. He emphasized that TROCEPT technology could unlock numerous opportunities to develop transformative cancer therapies.
Professor Hardev Pandha, Medical Director at Accession Therapeutics, elaborated on the innovative mechanism of TROCEPT-01, noting that it targets challenging cancers. He anticipates that clinical trials will validate the drug's localized production within tumours while establishing a robust safety profile and revealing initial efficacy indicators that could significantly benefit patients with limited treatment options.
Focus on Patient-Focused Results
Accession Therapeutics' clinical trials underscore the company’s commitment to finding effective treatments for conditions with substantial unmet medical needs. By enabling localised production of therapeutic proteins, TROCEPT-01 might offer an unprecedented approach to enhancing cancer treatment, minimizing systemic exposure, and providing a more effective alternative to traditional immunotherapeutics.
About Accession Therapeutics Limited
Founded in 2021, Accession Therapeutics Limited is a clinical-stage biopharmaceutical firm focused on developing a novel class of tumour-targeted immunotherapies through its proprietary TROCEPT platform. They are advancing a series of first-in-class therapies designed to improve cancer treatment by achieving localized therapeutic effects directly at the tumour site while reducing potential side effects associated with systemic therapies. The institution has successfully raised significant funding, amounting to USD $70 million, to further propel its research and development initiatives.
Frequently Asked Questions
What is TROCEPT-01?
TROCEPT-01 is a novel cancer immunotherapy designed to generate an immune checkpoint inhibitor within cancerous tumours while minimizing harm to healthy tissue.
What does the ATTEST trial aim to study?
The ATTEST trial aims to assess the safety, tolerability, pharmacokinetics, and initial efficacy of TROCEPT-01 in patients with advanced carcinomas.
How does TROCEPT-01 work?
TROCEPT-01 utilizes a viral mechanism that allows cancer cells to locally produce therapeutic proteins directly within the tumour, enhancing the anti-tumour response.
What are the potential advantages of TROCEPT-01?
The therapy may offer increased efficacy in treating difficult tumours and reduce the risk of adverse effects associated with conventional immunotherapy.
How is Accession Therapeutics supporting cancer treatment improvement?
Accession Therapeutics is dedicated to developing innovative therapies like TROCEPT-01, which aim to significantly improve outcomes for patients facing aggressive cancers.
